SCHEMBL2369978

SCHEMBL2369978

O=C(Nc1ncc(C(=O)O)s1)OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.57
CCNE1 P24864 5/20 0.53
CDK2 P24941 5/20 0.53
CCNE2 O96020 2/20 0.53
CDK5 Q00535 3/20 0.52
POLB P06746 1/20 0.51
GLS O94925 1/20 0.50
CCNB2 O95067 1/20 0.50
CDK1 P06493 1/20 0.50
CDK4 P11802 1/20 0.50
CCNB1 P14635 1/20 0.50
CCND1 P24385 1/20 0.50
CCNB3 Q8WWL7 1/20 0.50
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
ROCK2 O75116 1/20 0.46
MGLL Q99685 1/20 0.46
SCD O00767 1/20 0.46
TP53 P04637 1/20 0.45
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2370823 0.91 SMN1; SMN2 (0.57) SMN1; SMN2CCNE1CDK2CCNE2CDK5
SCHEMBL5956259 0.85 CCNE1 (0.67) SMN1; SMN2CCNE1CDK2CCNE2CDK5
SCHEMBL2370583 0.84 SMN1; SMN2 (0.57) SMN1; SMN2CCNE1CDK2CCNE2CDK5
SCHEMBL5836087 0.83 SMN1; SMN2 (0.56) SMN1; SMN2CCNE1CDK2CCNE2CDK5
SCHEMBL5835534 0.82 SMN1; SMN2 (0.55) SMN1; SMN2CCNE1CDK2CCNE2CDK5
SCHEMBL13934304 0.81 CDK2 (0.67) SMN1; SMN2CCNE1CDK2CCNE2CDK5
SCHEMBL18541910 0.80 MEN1 (0.65) SMN1; SMN2CDK2POLBNPC1RAB9A
SCHEMBL18541911 0.80 SMN1; SMN2 (0.56) SMN1; SMN2CCNE1CDK2CCNE2CDK5
SCHEMBL12590825 0.79 SMN1; SMN2 (0.48) SMN1; SMN2POLBMAPTALDH1A1
SCHEMBL2664690 0.78 GCK (0.61) SMN1; SMN2CCNE1CDK2CDK5NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130281708-A1 Process for the Production of 2-Amino-5-Fluorothiazole TAKEDA CALIFORNIA, INC. (US) 2013-10-24 US disclosed
US-20130281708-A1 Process for the Production of 2-Amino-5-Fluorothiazole TAKEDA CALIFORNIA, INC. (US) 2013-10-24 US disclosed
EP-2547667-A1 PROCESS FOR THE PRODUCTION OF 2-AMINO-5-FLUOROTHIAZOLE Takeda California, Inc. (US) 2013-01-23 EP disclosed
WO-2011115758-A1 PROCESS FOR THE PRODUCTION OF 2-AMINO-5-FLUOROTHIAZOLE TAKEDA SAN DIEGO, INC. (US) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281708-A1 Process for the Production of 2-Amino-5-Fluorothiazole GFPT1, PFAS, PFKFB4 SMN1; SMN2 3947/4885CCNE1 100/4885CDK2 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.